RA Capital Management Boosts Stake in Solid Biosciences with $22M Share Purchase
SLDB has more than doubled off its 52-week low of $3.79 on elevated volume (2.6× avg).
Summary
Major institutional investor RA Capital Management increased its stake in Solid Biosciences to 11.9% through over $22 million in share purchases, including participation in a recent ATM offering.
Key Events · Ownership and Investor Activity · SLDB
-
Significant Stake Increase
RA Capital Management, L.P. and its affiliates increased their beneficial ownership to 11.9% of Solid Biosciences' common stock, as reported on June 22, 2026.
-
$22.1 Million in Share Purchases
The firm purchased a total of 2,696,148 shares. This includes 338,100 shares via open market at a weighted-average price of $8.30 on June 18, 2026, and 2,358,048 shares in an ATM offering at $8.20 per share on June 22, 2026.
-
Institutional Confidence in Capital Strategy
This substantial investment follows the June 10, 2026 shareholder approval to double authorized common stock, signaling strong institutional support for the company's financing and growth plans.
Analysis · SLDB · Life Sciences
RA Capital Management, a significant institutional investor, has substantially increased its ownership in Solid Biosciences by purchasing over $22 million worth of common stock. This includes participation in an at-the-market (ATM) offering and open market buys, raising their total stake to 11.9%. This strong vote of confidence comes shortly after shareholders approved a significant increase in authorized common stock, indicating a positive outlook on the company's capital strategy and future prospects, especially as the stock trades near its 52-week high.
At the time of this filing, SLDB was trading at $9.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $910.7M. The 52-week trading range was $3.79 to $9.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.